Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/7760Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Tovey, M. G. | en |
| dc.contributor.author | Lallemand, C. | en |
| dc.contributor.author | Thyphronitis, G. | en |
| dc.date.accessioned | 2015-11-24T16:34:07Z | - |
| dc.date.available | 2015-11-24T16:34:07Z | - |
| dc.identifier.issn | 1431-6730 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/7760 | - |
| dc.rights | Default Licence | - |
| dc.subject | adjuvant | en |
| dc.subject | apoptosis | en |
| dc.subject | cytokines | en |
| dc.subject | interferons | en |
| dc.subject | toll-like receptor (tlr) | en |
| dc.subject | vaccination | en |
| dc.subject | quality-of-life | en |
| dc.subject | t-cells | en |
| dc.subject | dendritic cells | en |
| dc.subject | signaling pathways | en |
| dc.subject | direct stimulation | en |
| dc.subject | adaptive immunity | en |
| dc.subject | influenza vaccine | en |
| dc.subject | viral-infection | en |
| dc.subject | ifn-alpha | en |
| dc.subject | phase-ii | en |
| dc.title | Adjuvant activity of type I interferons | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | Doi 10.1515/Bc.2008.051 | - |
| heal.identifier.secondary | <Go to ISI>://000255439000009 | - |
| heal.identifier.secondary | http://www.degruyter.com/dg/viewarticle.fullcontentlink:pdfeventlink/contentUri?t:ac=j$002fbchm.2008.389.issue-5$002fbc.2008.051$002fbc.2008.051.xml | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιών | el |
| heal.publicationDate | 2008 | - |
| heal.abstract | Type I interferons (IFNs) produced primarily by plasmacytoid dendritic cells (pDCs) as part of the innate immune response to infectious agents induce the maturation of myeloid DCs and enhance antigen presentation. Type I IFNs also enhance apoptosis of virus-infected cells, stimulate cross priming and enhanced presentation of viral peptides. Type I IFNs are powerful polyclonal B-cell activators that induce a strong primary humoral immune response characterized by isotype switching and protection against virus challenge. Type I IFNs stimulate an IgG2a antibody response characteristic of Th1 immunity when ad-mixed with influenza virus vaccine and injected intramuscurarly (i.m.) or administered intranasally. The adjuvant activity of type I IFNs has been shown to involve direct effects of IFN on B-cells, effects on T-cells, as well as effects on antigen presentation. Oromucosal administration of type I IFNs concomitantly with i.m. injection of vaccine alone can also enhance the antibody response to influenza vaccination by enhancing trafficking of antigen-presenting cells towards the site of vaccination. Recombinant IFNs are potent adjuvants that may find application in both parenterally and mucosally administered vaccines. | en |
| heal.journalName | Biol Chem | en |
| heal.journalType | peer reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Tovey-2008-Adjuvant activity of.pdf | 74.45 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License
